Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Navamedic

Less than 1K followers

NAVA

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor views

Navamedic is a Nordic pharmaceutical company that supplies pharmaceuticals, OTC, medical nutrition products for rare diagnoses and medical devices to hospitals and pharmacies in areas such as obesity, women's health, urology, gastrointestinal and pain. Navamedic operates in the Nordic countries, the Baltics and Benelux but is also represented in the UK and Greece. The company was established in 1999 and is headquartered in Oslo.

Read more
Market cap
-
Turnover
-
Revenue
565.36M
EBIT %
2.19 %
P/E
-
Dividend yield-%
-
Financial calendar
12.2
2027

Annual report '26

29.4
2027

General meeting '27

29.4
2027

Interim report Q1'27

All
Press releases
3rd party
ShowingAll content types

Regulatory press release29.10.2026, 16.02

Navamedic ASA: Mandatory notification of trade

Navamedic
Regulatory press release29.10.2026, 14.32

Navamedic ASA: Mandatory notification of trade

Navamedic
Regulatory press release29.10.2026, 12.45

Navamedic ASA: Mandatory notification of trade

Navamedic

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release29.10.2026, 10.38

NAVA: Financial calendar

Navamedic
Regulatory press release29.10.2026, 07.00

Navamedic ASA: Profitability improvement driven by product mix and cost discipline despite decreased revenue

Navamedic
Regulatory press release26.10.2026, 09.45

Navamedic ASA: Invitation to presentation of third quarter 2026 results

Navamedic
Regulatory press release20.10.2026, 08.45

NAVA: Prolongation of Mysimba® distribution agreement

Navamedic
Press release20.10.2026, 08.45

Navamedic ASA: Prolongation of Mysimba® distribution agreement

Navamedic
Regulatory press release02.09.2026, 16.50

Navamedic ASA: Mandatory notification of trade

Navamedic
Regulatory press release14.08.2026, 07.00

Navamedic ASA: Growth and double-digit adjusted EBITDA margin in Q2 and first half 2026

Navamedic
Regulatory press release14.08.2026, 07.00

Navamedic ASA: Growth and double-digit adjusted EBITDA margin in Q2 and first half 2026

Navamedic
Regulatory press release10.08.2026, 08.31

Navamedic ASA: Invitation to presentation of second quarter and first half year 2026 results

Navamedic
Regulatory press release26.06.2026, 17.15

Navamedic ASA: Mandatory notification of trade

Navamedic
Regulatory press release16.06.2026, 07.57

Navamedic ASA: Change in leadership

Navamedic
Regulatory press release21.05.2026, 15.27

NAVA: Navamedic launches Virono®- the first single-dose over-the-counter cold sore tablet

Navamedic
Press release21.05.2026, 15.27

Navamedic ASA: Navamedic launches Virono®- the first single-dose over-the-counter cold sore tablet

Navamedic
Regulatory press release20.05.2026, 12.45

NAVA: Major shareholder disclosure in Navamedic ASA

Navamedic
Regulatory press release18.05.2026, 16.00

Navamedic ASA: Mandatory notification of trade

Navamedic
Regulatory press release23.04.2026, 16.07

Navamedic ASA: Minutes of Annual General Meeting

Navamedic
Regulatory press release23.04.2026, 16.06

Navamedic ASA: Minutes of Annual General Meeting

Navamedic